VentriPoint Diagnostics Ltd. (CVE:VPT - Get Free Report) Director Robert Hodgkinson acquired 75,000 shares of the company's stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of C$0.21 per share, for a total transaction of C$15,900.00.
Robert Hodgkinson also recently made the following trade(s):
- On Thursday, April 18th, Robert Hodgkinson purchased 36,500 shares of VentriPoint Diagnostics stock. The shares were acquired at an average cost of C$0.21 per share, with a total value of C$7,774.50.
VentriPoint Diagnostics Stock Performance
CVE VPT opened at C$0.21 on Tuesday. VentriPoint Diagnostics Ltd. has a fifty-two week low of C$0.12 and a fifty-two week high of C$0.36. The company has a debt-to-equity ratio of 32.61, a quick ratio of 6.67 and a current ratio of 2.06. The firm has a market capitalization of C$32.93 million, a P/E ratio of -7.00 and a beta of 0.39. The stock has a 50-day simple moving average of C$0.25 and a two-hundred day simple moving average of C$0.24.
About VentriPoint Diagnostics
(
Get Free Report)
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
